Lung Cancer, Non-Small Cell
Conditions
Keywords
Non-Small Cell Lung Cancer, Immunotherapy, Antigen-Specific
Brief summary
The purpose of this study was to test a potential new kind of anti-cancer treatment, called PRAME immunotherapy in resected patients with lung cancer. Based on scientific and medical relevance, the clinical study was ended on 24 August 2016. The participants were no longer enrolled in the study, the follow ups on subjects were stopped and the collection and analysis of samples for further research purposes was stopped. After the stop to recruitment, the study was unblinded, as per the amended protocol, the study treatment was continued and completed with the subjects of the active treatment group who were willing to continue. Subjects in the placebo group were withdrawn. There was no longer an active follow-up of patients after discontinuation or completion of the treatment. The study ended 30 days after the last dose was administered. As a result, primary and secondary objectives were not assessed as planned. All clinical and safety data collected in the study were analysed descriptively. For each biological sample already collected in the scope of this study and not tested yet, testing was not performed by default, except if a scientific rationale remained relevant despite the premature termination of the study.
Detailed description
During the treatment period, safety monitoring continued as initially foreseen. Reporting of post-study adverse events (AEs) and serious AEs (SAEs) continued as per protocol. In the best interest of the patient, no more biological samples for protocol research purposes (i.e. serum sampling for humoral immunity, whole blood sampling for pharmacogenetics) were taken.
Interventions
BIOLOGICALRecombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A
Intramuscular administration
BIOLOGICALPlacebo
Intramuscular administration
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient has radically resected NSCLC * The NSCLC is of pathological stage IA-T1b, IB, II or IIIA NSCLC The surgical technique for resection of the patient's tumor is anatomical, involving at least a segmentectomy The patient's tumor shows expression of PRAME. * The patient is ≥ 18 years of age at the time of first consent. * Written informed consent has been obtained from the patient prior to performance of any study-specific procedure. * The patient is free of disease (no residual tumor, no loco-regional recurrence, no distant metastasis), as confirmed by a post- thoracic surgery contrast-enhanced computed tomography (CT scan) of the chest, upper abdomen and by a contrast-enhanced CT scan or Magnetic Resonance Imaging (MRI) of the brain. Other examinations should be performed as clinically indicated. * Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or 2 at the time of randomization * Adequate bone-marrow reserve, adequate renal, hepatic and adrenal function as assessed by standard laboratory criteria * If the patient is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to administration of study product, have a negative pregnancy test and continue such precautions during all study treatment period and for 2 months after last treatment administration. * Patients who the investigator believes can and will comply with the requirements of this protocol (e.g. return for active follow-up visits).
Exclusion criteria
* The patient is diagnosed with a concomitant malignancy and/or has a history of malignancy within the past five years or has had a malignancy that has been in complete remission for less than 5 years. Patients with effectively treated non - melanoma skin cancers or effectively treated carcinoma in situ of the cervix both of which in remission for less than 5 years will be eligible. * The patient has received any anti-cancer specific treatment, including radiotherapy, immunotherapy, hormonal therapy, chemotherapy or neo-adjuvant chemotherapy, except for: * Administration of adjuvant platinum-based doublet chemotherapy for the treatment of the current NSCLC allowed between surgery and randomization. * Treatment of previous malignancies as allowed by the protocol. * The patient has been diagnosed with a Potential Immune-Mediated Disease (pIMD). Patients with vitiligo are not excluded from the study. * The patient has a history of confirmed adrenal dysfunction. * The patient requires concomitant treatment with any immunosuppressive agent, or with systemic corticosteroids prescribed for chronic treatment (more than 7 consecutive days). * The patient needs chronic long term oxygen therapy (LTOT). The patient has medically uncontrolled congestive heart failure or hypertension, unstable heart disease or uncontrolled arrhythmia at the time of randomization. * The patient has an uncontrolled bleeding disorder. * The patient has undergone splenectomy. * The patient is known to be Human Immunodeficiency Virus (HIV)-positive. * The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the trial procedures. * The patient has other concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk. * The patient has a history of allergic disease or reactions likely to be exacerbated by any component of the study investigational product. * The patient has received any investigational or non-registered product within the 30 days preceding randomization, or planned use during the study period. * For female patients: the patient is pregnant or lactating or is planning to become pregnant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to Occurrence of Any Recurrence of Disease | During the entire study (From Week 1 to Week 112) | Time to occurrence of any recurrence of disease was expressed in terms of rate: Person-year rate in each group = number of patients reporting at least one recurrence of disease (n)/ sum of follow-up period expressed in years (T\[year)\]) As a consequence of the decision to stop the PRAME-AS15-NSC-002 (ADJ) study, not all data were available for a full analysis. The median follow-up time was 10.3 months in the GSK2302032A group and 5.7 months in the Placebo group. Considering that two Phase III studies with recMAGE-A3 + AS15 failed to demonstrate clinical efficacy of the MAGE-A3 antigen specific cancer immunotherapeutic, GSK decided to stop the development of all recombinant protein based cancer vaccines and to stop recruitment in all the ongoing clinical studies. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Lung-cancer-specific Survival | During the entire study (From Week 1 to Week 112) | Lung-cancer specific survival was defined as defined as the interval from randomization to the date of death due to lung cancer; deaths due to other or unknown causes were censored at the date of death. Considering that two Phase III studies with recMAGE-A3 + AS15 failed to demonstrate clinical efficacy of the MAGE-A3 antigen specific cancer immunotherapeutic, GSK decided to stop the development of all recombinant protein based cancer vaccines and to stop recruitment in all the ongoing clinical studies. Therefore, based on scientific and medical relevance, the decision was made to stop patient enrollment in the PRAME-AS15-NSC-002 (ADJ) clinical study and to stop follow-up visits, further sample collection for research purposes and the analysis of samples for research purposes. In consequence, the primary and secondary outcomes were not analysed as planned and clinical data for this outcome was not collected. |
| Disease-free Specific Survival (DFSS) | During the entire study (From Week 1 to Week 112) | DFSS was defined as the interval from randomization to the date of first recurrence of disease or date of death due to lung cancer, whichever occurs first. Patients without recurrence or death due to lung cancer were censored at the date of last assessment. Considering that two Phase III studies with recMAGE-A3 + AS15 failed to demonstrate clinical efficacy of the MAGE-A3 antigen specific cancer immunotherapeutic, GSK decided to stop the development of all recombinant protein based cancer vaccines and to stop recruitment in all the ongoing clinical studies. Therefore, based on scientific and medical relevance, the decision was made to stop patient enrollment in the PRAME-AS15-NSC-002 (ADJ) clinical study and to stop follow-up visits, further sample collection for research purposes and the analysis of samples for research purposes. In consequence, the primary and secondary outcomes were not analysed as planned and clinical data for this outcome was not collected. |
| DFS (Disease-free Survival) at 2, 3, 4 and 5 Years After Randomization | During the entire follow-up period (From year 2 to Year 5) | Defined as the time from randomization to either the date of first recurrence of the disease or the date of death (whatever the cause), whichever occurred first. The 5-year active follow-up period planned in the initial study protocol was cancelled per Protocol Amendment 2, hence this analysis was not performed. |
| Number of Subjects With Any Unsolicited Adverse Events (AEs) | Within the 31-day (Days 0-30) post-vaccine administration period | Unsolicited AEs covered any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. |
| Overall Survival (OS) | During the entire study (From Week 1 to Week 112) | OS was defined as the interval from randomization to the date of death, irrespective of the cause of death; patients still alive were censored at the last visit they are known to be alive. Considering that two Phase III studies with recMAGE-A3 + AS15 failed to demonstrate clinical efficacy of the MAGE-A3 antigen specific cancer immunotherapeutic, GSK decided to stop the development of all recombinant protein based cancer vaccines and to stop recruitment in all the ongoing clinical studies. Therefore, based on scientific and medical relevance, the decision was made to stop patient enrollment in the PRAME-AS15-NSC-002 (ADJ) clinical study and to stop follow-up visits, further sample collection for research purposes and the analysis of samples for research purposes. In consequence, the primary and secondary outcomes were not analysed as planned and clinical data for this outcome was not collected. |
| Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | During the entire study period (From Week 1 to Week 112) | Hematological and biochemical parameters assessed were tabulated by maximum grade versus baseline, by CTCAE = Common Terminology Criteria for Adverse Events version 4.0 (Grade 1= mild; Grade 2= moderate; Grade 3= severe; Grade 4= life-threatening; Grade 5 = death; Grade Unknown) and by the type of abnormality (e.g. increased, decreased, prolonged, etc.). Some parameters (e.g. Anemia) already comprise within their definition the type of abnormality presented. |
| Number of Subjects With Any Serious Adverse Events (SAEs) | During the entire study (From Week 1 to Week 112) | SAEs assessed included medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity. An event that was part of the natural course of the disease under study (i.e., disease progression, recurrence) was captured in the study as an efficacy measure; therefore it did not need to be reported as an SAE. |
| Number of Subjects With Any Adverse Events (AEs) by Intensity Grade. | From Week 0 to Week 112 | Grading was done as per the Common Terminology Criteria for Adverse Events (CTCAE) of the U.S. National Cancer Institute, version 4.0. The intensity grades assessed were: 1, 2, 3, 4, 5 and Unknown. |
| Anti-PRAME Antibody Concentrations | At each defined time point from Week 0 till Concluding Visit (Week 112) | Considering that two Phase III studies with recMAGE-A3 + AS15 failed to demonstrate clinical efficacy of the MAGE-A3 antigen specific cancer immunotherapeutic, GSK decided to stop the development of all recombinant protein based cancer vaccines and to stop recruitment in all the ongoing clinical studies. Therefore, based on scientific and medical relevance, the decision was made to stop patient enrollment in the PRAME-AS15-NSC-002 (ADJ) clinical study and to stop follow-up visits, further sample collection for research purposes and the analysis of samples for research purposes. In consequence, the primary and secondary outcomes were not analysed as planned and clinical data for this outcome was not collected. |
Countries
Estonia, France, Germany, Japan, Poland, Russia, South Korea, United Kingdom, United States
Participant flow
Recruitment details
On 18 July 2014, the recruitment was stopped and the study was un-blinded. The study continued only with patients from the active treatment group who decided to stay in the study, however objective and outcomes were not assessed as planned.
Pre-assignment details
Among 137 enrolled patients, 4 patients didn't receive any study product dose and hence they were not taken into account for study start.
Participants by arm
| Arm | Count |
|---|---|
| GSK2302032A Group The patients received 13 administrations GSK2302032A product, as per the following schedule: For the first five doses: 1 dose every 3 weeks. For the remaining 8 doses: 1 dose every 12 weeks. | 86 |
| Placebo Group The patients received 13 administrations of a placebo, as per the following schedule: For the first five doses: 1 dose every 3 weeks. For the remaining 8 doses: 1 dose every 12 weeks. | 47 |
| Total | 133 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 2 | 0 |
| Overall Study | Migrated/moved from the study area | 1 | 0 |
| Overall Study | Other | 55 | 43 |
| Overall Study | Recurrence | 2 | 0 |
| Overall Study | Withdrawal by Subject | 3 | 1 |
Baseline characteristics
| Characteristic | GSK2302032A Group | Placebo Group | Total |
|---|---|---|---|
| Age, Continuous | 64.5 Years STANDARD_DEVIATION 8.68 | 62.7 Years STANDARD_DEVIATION 9.28 | 63.86 Years STANDARD_DEVIATION 8.9 |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Sex: Female, Male Female | 26 Participants | 13 Participants | 39 Participants |
| Sex: Female, Male Male | 60 Participants | 34 Participants | 94 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 86 | 0 / 47 |
| other Total, other adverse events | 78 / 86 | 21 / 47 |
| serious Total, serious adverse events | 14 / 86 | 0 / 47 |
Outcome results
Primary
Time to Occurrence of Any Recurrence of Disease
Time to occurrence of any recurrence of disease was expressed in terms of rate: Person-year rate in each group = number of patients reporting at least one recurrence of disease (n)/ sum of follow-up period expressed in years (T\[year)\]) As a consequence of the decision to stop the PRAME-AS15-NSC-002 (ADJ) study, not all data were available for a full analysis. The median follow-up time was 10.3 months in the GSK2302032A group and 5.7 months in the Placebo group. Considering that two Phase III studies with recMAGE-A3 + AS15 failed to demonstrate clinical efficacy of the MAGE-A3 antigen specific cancer immunotherapeutic, GSK decided to stop the development of all recombinant protein based cancer vaccines and to stop recruitment in all the ongoing clinical studies.
Time frame: During the entire study (From Week 1 to Week 112)
Population: The analysis was performed on the Total Treated population that included all the subjects who had received at least one dose of the study product.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| GSK2302032A Group | Time to Occurrence of Any Recurrence of Disease | 0.217 person-year rate |
| Placebo Group | Time to Occurrence of Any Recurrence of Disease | 0.067 person-year rate |
Comparison: Estimates of Hazard Ratio (HR) and their 95% Confidence Interval (CI) were obtained by Cox regression modelling.The Likelihood ratio test was used to compare the groups. The Cox proportional hazard regression was stratified by previous treatment \[Chemotherapy (CT) vs. no-CT\] and disease stage.p-value: 0.142295% CI: [0.6, 35.167]Regression, Cox
Secondary
Anti-PRAME Antibody Concentrations
Considering that two Phase III studies with recMAGE-A3 + AS15 failed to demonstrate clinical efficacy of the MAGE-A3 antigen specific cancer immunotherapeutic, GSK decided to stop the development of all recombinant protein based cancer vaccines and to stop recruitment in all the ongoing clinical studies. Therefore, based on scientific and medical relevance, the decision was made to stop patient enrollment in the PRAME-AS15-NSC-002 (ADJ) clinical study and to stop follow-up visits, further sample collection for research purposes and the analysis of samples for research purposes. In consequence, the primary and secondary outcomes were not analysed as planned and clinical data for this outcome was not collected.
Time frame: At each defined time point from Week 0 till Concluding Visit (Week 112)
Population: Anti-PRAME antibody data was not collected.
Secondary
DFS (Disease-free Survival) at 2, 3, 4 and 5 Years After Randomization
Defined as the time from randomization to either the date of first recurrence of the disease or the date of death (whatever the cause), whichever occurred first. The 5-year active follow-up period planned in the initial study protocol was cancelled per Protocol Amendment 2, hence this analysis was not performed.
Time frame: During the entire follow-up period (From year 2 to Year 5)
Population: The 5-Year Follow-Up Disease Free Survival data were not collected.
Secondary
Disease-free Specific Survival (DFSS)
DFSS was defined as the interval from randomization to the date of first recurrence of disease or date of death due to lung cancer, whichever occurs first. Patients without recurrence or death due to lung cancer were censored at the date of last assessment. Considering that two Phase III studies with recMAGE-A3 + AS15 failed to demonstrate clinical efficacy of the MAGE-A3 antigen specific cancer immunotherapeutic, GSK decided to stop the development of all recombinant protein based cancer vaccines and to stop recruitment in all the ongoing clinical studies. Therefore, based on scientific and medical relevance, the decision was made to stop patient enrollment in the PRAME-AS15-NSC-002 (ADJ) clinical study and to stop follow-up visits, further sample collection for research purposes and the analysis of samples for research purposes. In consequence, the primary and secondary outcomes were not analysed as planned and clinical data for this outcome was not collected.
Time frame: During the entire study (From Week 1 to Week 112)
Population: Disease free-specific survival data was not collected.
Secondary
Lung-cancer-specific Survival
Lung-cancer specific survival was defined as defined as the interval from randomization to the date of death due to lung cancer; deaths due to other or unknown causes were censored at the date of death. Considering that two Phase III studies with recMAGE-A3 + AS15 failed to demonstrate clinical efficacy of the MAGE-A3 antigen specific cancer immunotherapeutic, GSK decided to stop the development of all recombinant protein based cancer vaccines and to stop recruitment in all the ongoing clinical studies. Therefore, based on scientific and medical relevance, the decision was made to stop patient enrollment in the PRAME-AS15-NSC-002 (ADJ) clinical study and to stop follow-up visits, further sample collection for research purposes and the analysis of samples for research purposes. In consequence, the primary and secondary outcomes were not analysed as planned and clinical data for this outcome was not collected.
Time frame: During the entire study (From Week 1 to Week 112)
Population: Lung-cancer specific survival data was not collected.
Secondary
Number of Subjects With Any Abnormal Hematological and Biochemical Parameters
Hematological and biochemical parameters assessed were tabulated by maximum grade versus baseline, by CTCAE = Common Terminology Criteria for Adverse Events version 4.0 (Grade 1= mild; Grade 2= moderate; Grade 3= severe; Grade 4= life-threatening; Grade 5 = death; Grade Unknown) and by the type of abnormality (e.g. increased, decreased, prolonged, etc.). Some parameters (e.g. Anemia) already comprise within their definition the type of abnormality presented.
Time frame: During the entire study period (From Week 1 to Week 112)
Population: This analysis was performed on the Total Treated population, which included all the patients who had received at least one dose of the study product and for whom blood results were available for the respective parameter assessed.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Aspartate aminotransferase increased | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyperkalemia | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alkaline Phosphatase increased | Grade 3 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyperkalemia | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Aspartate aminotransferase increased | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyperkalemia | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alanine aminotransferase increased | Grade 2 | 1 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypernatremia | Grade 1 | 13 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Blood bilirubin increased | Grade 1 | 7 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypernatremia | Grade 2 | 4 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alkaline Phosphatase increased | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypernatremia | Grade 3 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Blood bilirubin increased | Grade 2 | 1 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypernatremia | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Activated partial thromboplastin time prolonged | Grade 1 | 26 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypernatremia | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Blood bilirubin increased | Grade 3 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypernatremia | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alkaline Phosphatase increased | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypoalbuminemia | Grade 1 | 18 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Blood bilirubin increased | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypoalbuminemia | Grade 2 | 3 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alanine aminotransferase increased | Grade 3 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypoalbuminemia | Grade 3 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Blood bilirubin increased | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypoalbuminemia | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alkaline Phosphatase increased | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Activated partial thromboplastin time prolonged | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypoalbuminemia | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Creatinine increased | Grade 1 | 15 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypokalemia | Grade 1 | 3 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Anemia | Grade 1 | 36 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypokalemia | Grade 2 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Creatinine increased | Grade 2 | 3 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypokalemia | Grade 3 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypokalemia | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Creatinine increased | Grade 3 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypokalemia | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Anemia | Grade 2 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypokalemia | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Creatinine increased | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyponatremia | Grade 1 | 10 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyponatremia | Grade 2 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Creatinine increased | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyponatremia | Grade 3 | 1 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Anemia | Grade 3 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyponatremia | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Creatinine increased | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyponatremia | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alanine aminotransferase increased | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyponatremia | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Gamma-glutamyl transferase increased | Grade 1 | 14 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count decreased | Grade 1 | 19 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Anemia | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count decreased | Grade 2 | 3 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Gamma-glutamyl transferase increased | Grade 2 | 7 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count decreased | Grade 3 | 2 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Activated partial thromboplastin time prolonged | Unknown | 1 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count decreased | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Gamma-glutamyl transferase increased | Grade 3 | 2 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count decreased | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Anemia | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count decreased | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Gamma-glutamyl transferase increased | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count increased | Grade 1 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alanine aminotransferase increased | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count increased | Grade 2 | 2 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Gamma-glutamyl transferase increased | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count increased | Grade 3 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Anemia | Unknown | 1 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count increased | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Gamma-glutamyl transferase increased | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count increased | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Activated partial thromboplastin time prolonged | Grade 2 | 1 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count increased | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hemoglobin increased | Grade 1 | 5 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Neutrophil count decreased | Grade 1 | 9 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Aspartate aminotransferase increased | Grade 1 | 15 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Neutrophil count decreased | Grade 2 | 4 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hemoglobin increased | Grade 2 | 1 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Neutrophil count decreased | Grade 3 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alkaline Phosphatase increased | Grade 1 | 17 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Neutrophil count decreased | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hemoglobin increased | Grade 3 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Neutrophil count decreased | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Aspartate aminotransferase increased | Grade 2 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Neutrophil count decreased | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hemoglobin increased | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Platelet count decreased | Grade 1 | 6 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alanine aminotransferase increased | Grade 1 | 17 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Platelet count decreased | Grade 2 | 1 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hemoglobin increased | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Platelet count decreased | Grade 3 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Aspartate aminotransferase increased | Grade 3 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Platelet count decreased | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hemoglobin increased | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Platelet count decreased | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypoalbuminemia | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Platelet count decreased | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alkaline Phosphatase increased | Grade 2 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | White blood cell decreased | Grade 1 | 7 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyperkalemia | Grade 1 | 22 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | White blood cell decreased | Grade 2 | 1 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | White blood cell decreased | Grade 3 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyperkalemia | Grade 2 | 4 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | White blood cell decreased | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Activated partial thromboplastin time prolonged | Grade 4 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | White blood cell decreased | Grade 5 | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyperkalemia | Grade 3 | 1 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | White blood cell decreased | Unknown | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Blood bilirubin increased | Unknown | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | White blood cell decreased | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Activated partial thromboplastin time prolonged | Grade 1 | 8 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Activated partial thromboplastin time prolonged | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Activated partial thromboplastin time prolonged | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Activated partial thromboplastin time prolonged | Unknown | 2 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alanine aminotransferase increased | Grade 1 | 6 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alanine aminotransferase increased | Grade 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alanine aminotransferase increased | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alanine aminotransferase increased | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alanine aminotransferase increased | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alkaline Phosphatase increased | Grade 1 | 5 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alkaline Phosphatase increased | Grade 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alkaline Phosphatase increased | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alkaline Phosphatase increased | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alkaline Phosphatase increased | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Alkaline Phosphatase increased | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Anemia | Grade 1 | 17 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Anemia | Grade 2 | 2 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Anemia | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Anemia | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Anemia | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Anemia | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Aspartate aminotransferase increased | Grade 1 | 5 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Aspartate aminotransferase increased | Grade 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Aspartate aminotransferase increased | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Aspartate aminotransferase increased | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Aspartate aminotransferase increased | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Blood bilirubin increased | Grade 1 | 2 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Blood bilirubin increased | Grade 2 | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Blood bilirubin increased | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Blood bilirubin increased | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Blood bilirubin increased | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Blood bilirubin increased | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Creatinine increased | Grade 1 | 7 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Creatinine increased | Grade 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Creatinine increased | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Creatinine increased | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Creatinine increased | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Creatinine increased | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Gamma-glutamyl transferase increased | Grade 1 | 11 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Gamma-glutamyl transferase increased | Grade 2 | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Gamma-glutamyl transferase increased | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Gamma-glutamyl transferase increased | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Gamma-glutamyl transferase increased | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Gamma-glutamyl transferase increased | Unknown | 2 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hemoglobin increased | Grade 1 | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hemoglobin increased | Grade 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hemoglobin increased | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hemoglobin increased | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hemoglobin increased | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hemoglobin increased | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyperkalemia | Grade 1 | 12 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyperkalemia | Grade 2 | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyperkalemia | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyperkalemia | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyperkalemia | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyperkalemia | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypernatremia | Grade 1 | 6 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypernatremia | Grade 2 | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypernatremia | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypernatremia | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypernatremia | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypernatremia | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypoalbuminemia | Grade 1 | 10 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypoalbuminemia | Grade 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypoalbuminemia | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypoalbuminemia | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypoalbuminemia | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypoalbuminemia | Unknown | 2 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypokalemia | Grade 1 | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypokalemia | Grade 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypokalemia | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypokalemia | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypokalemia | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hypokalemia | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyponatremia | Grade 1 | 6 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyponatremia | Grade 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyponatremia | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyponatremia | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyponatremia | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Hyponatremia | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count decreased | Grade 1 | 8 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count decreased | Grade 2 | 2 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count decreased | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count decreased | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count decreased | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count decreased | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count increased | Grade 1 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count increased | Grade 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count increased | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count increased | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count increased | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Lymphocyte count increased | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Neutrophil count decreased | Grade 1 | 7 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Neutrophil count decreased | Grade 2 | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Neutrophil count decreased | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Neutrophil count decreased | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Neutrophil count decreased | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Neutrophil count decreased | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Platelet count decreased | Grade 1 | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Platelet count decreased | Grade 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Platelet count decreased | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Platelet count decreased | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Platelet count decreased | Grade 5 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | Platelet count decreased | Unknown | 1 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | White blood cell decreased | Grade 1 | 4 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | White blood cell decreased | Grade 2 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | White blood cell decreased | Grade 3 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | White blood cell decreased | Grade 4 | 0 Participants |
| Placebo Group | Number of Subjects With Any Abnormal Hematological and Biochemical Parameters | White blood cell decreased | Grade 5 | 0 Participants |
Secondary
Number of Subjects With Any Adverse Events (AEs) by Intensity Grade.
Grading was done as per the Common Terminology Criteria for Adverse Events (CTCAE) of the U.S. National Cancer Institute, version 4.0. The intensity grades assessed were: 1, 2, 3, 4, 5 and Unknown.
Time frame: From Week 0 to Week 112
Population: This analysis was performed on the Total Treated population, which included all the patients who had received at least one dose of the study product.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK2302032A Group | Number of Subjects With Any Adverse Events (AEs) by Intensity Grade. | Any Grade 3 AEs | 15 Participants |
| GSK2302032A Group | Number of Subjects With Any Adverse Events (AEs) by Intensity Grade. | Any Grade 5 AEs | 1 Participants |
| GSK2302032A Group | Number of Subjects With Any Adverse Events (AEs) by Intensity Grade. | Any Grade 4 AEs | 3 Participants |
| GSK2302032A Group | Number of Subjects With Any Adverse Events (AEs) by Intensity Grade. | Any Grade 2 AEs | 29 Participants |
| GSK2302032A Group | Number of Subjects With Any Adverse Events (AEs) by Intensity Grade. | Any Grade Unknown AEs | 0 Participants |
| GSK2302032A Group | Number of Subjects With Any Adverse Events (AEs) by Intensity Grade. | Any Grade 1 AEs | 35 Participants |
| Placebo Group | Number of Subjects With Any Adverse Events (AEs) by Intensity Grade. | Any Grade Unknown AEs | 0 Participants |
| Placebo Group | Number of Subjects With Any Adverse Events (AEs) by Intensity Grade. | Any Grade 1 AEs | 17 Participants |
| Placebo Group | Number of Subjects With Any Adverse Events (AEs) by Intensity Grade. | Any Grade 2 AEs | 8 Participants |
| Placebo Group | Number of Subjects With Any Adverse Events (AEs) by Intensity Grade. | Any Grade 3 AEs | 2 Participants |
| Placebo Group | Number of Subjects With Any Adverse Events (AEs) by Intensity Grade. | Any Grade 5 AEs | 0 Participants |
| Placebo Group | Number of Subjects With Any Adverse Events (AEs) by Intensity Grade. | Any Grade 4 AEs | 0 Participants |
Secondary
Number of Subjects With Any Serious Adverse Events (SAEs)
SAEs assessed included medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity. An event that was part of the natural course of the disease under study (i.e., disease progression, recurrence) was captured in the study as an efficacy measure; therefore it did not need to be reported as an SAE.
Time frame: During the entire study (From Week 1 to Week 112)
Population: This analysis was performed on the Total Treated population, which included all the patients who had received at least one dose of the study product.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK2302032A Group | Number of Subjects With Any Serious Adverse Events (SAEs) | 14 Participants |
| Placebo Group | Number of Subjects With Any Serious Adverse Events (SAEs) | 0 Participants |
Secondary
Number of Subjects With Any Unsolicited Adverse Events (AEs)
Unsolicited AEs covered any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: Within the 31-day (Days 0-30) post-vaccine administration period
Population: This analysis was performed on the Total Treated population, which included all the patients who had received at least one dose of the study product.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK2302032A Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | 78 Participants |
| Placebo Group | Number of Subjects With Any Unsolicited Adverse Events (AEs) | 21 Participants |
Secondary
Overall Survival (OS)
OS was defined as the interval from randomization to the date of death, irrespective of the cause of death; patients still alive were censored at the last visit they are known to be alive. Considering that two Phase III studies with recMAGE-A3 + AS15 failed to demonstrate clinical efficacy of the MAGE-A3 antigen specific cancer immunotherapeutic, GSK decided to stop the development of all recombinant protein based cancer vaccines and to stop recruitment in all the ongoing clinical studies. Therefore, based on scientific and medical relevance, the decision was made to stop patient enrollment in the PRAME-AS15-NSC-002 (ADJ) clinical study and to stop follow-up visits, further sample collection for research purposes and the analysis of samples for research purposes. In consequence, the primary and secondary outcomes were not analysed as planned and clinical data for this outcome was not collected.
Time frame: During the entire study (From Week 1 to Week 112)
Population: Overall survival data was not collected.